FindTrial
Sign In

Clinical observation and prognostic follow-up of gamma globulin treatment in children with endocardial fibroblastosis

Clinical observation and prognostic follow-up of gamma globulin treatment in children with endocardial fibroblastosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100048486
Enrollment
Unknown
Registered
2021-07-09
Start date
2021-07-08
Completion date
Unknown
Last updated
2022-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endocardial elastofibrosis in children

Interventions

Group 1:Gamma globulin therapy
Group 2:Not treated with gamma globulin

Sponsors

The Seventh Medical Center of PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1. Aged < 18 years; 2. Children's endocardial fibroelastosis caused by various reasons; 3. Parents agree to use gamma globulin therapy.

Exclusion criteria

Exclusion criteria: Suffering from other diseases other than childhood endocardial fibroelastosis.

Design outcomes

Primary

MeasureTime frame
mortality;—

Countries

China

Contacts

Public ContactZhou Gengxu

Chinese PLA General Hospital

cardiacsurgeon@126.com+86 15001395415

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026